Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Stellate Ganglion Block in the Treatment of Posttraumatic Stress Disorder: Outcome Evaluation, Mechanism of Action, and Integration in Care - A Phase III Randomized Controlled Trial

NCT05427500 is registered in ClinicalTrials.gov with The Royal's Institute of Mental Health Research as lead sponsor.

NCT NCT05427500
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05427500 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Stellate Ganglion Block in the Treatment of Posttraumatic Stress Disorder: Outcome Evaluation, Mechanism of Action, and Integration in Care - A Phase III Randomized Controlled Trial
Lead sponsor
The Royal's Institute of Mental Health Research
Phase
Phase 3
Overall status
Enrolling by invitation
Start date
March 30, 2024
Completion date
January 30, 2027
Enrollment
54 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ptsd